Hyperbaric oxygen therapy for COVID-19 patients with respiratory distress

COVID-19
Written By Karan singh

This is a single-center clinical trial of 20 COVID-19 patients aged 30 to 79 years being treated with 5 sessions of hyperbaric oxygen therapy at 2.0 ATA (90 minutes) at NYU Winthrop Hospital from March 31 to April 28, 2020.

“The results demonstrated the safety of hyperbaric oxygen among COVID-19 patients and strongly suggests the need for a well-designed, multi-center randomized control trial” <view study>

Karan singh
Previous

Hyperbaric oxygen therapy may be effective to improve hypoxemia in patients with severe COVID-2019 pneumonia: two case reports
Next

Hyperbaric oxygen therapy shows benefit for pulmonary fibrosis